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The Saccharomyces cerevisiae genome encodes 15 full-
size ATP binding cassette transporters (ABC), of which
PDR5, SNQ2, and YOR1 are known to be regulated by the
transcription factors Pdr1p and Pdr3p (pleiotropic drug
resistance). We have identified two new ABC transport-
er-encoding genes, PDR10 and PDR15, which were up-
regulated by the PDR1–3 mutation. These genes, as well
as four other ABC transporter-encoding genes, were de-
leted in order to study the properties of Yor1p. The
PDR1–3 gain-of-function mutant was then used to over-
produce Yor1p up to 10% of the total plasma membrane
proteins. Overexpressed Yor1p was photolabeled by
[g-32P]2*,3*-O-(2,4,6-trinitrophenyl)-8-azido-ATP (K0.5 5
45 mM) and inhibited by ATP (KD 5 0.3 mM) in plasma
membranes. Solubilization and partial purification on
sucrose gradient allowed to detect significant Yor1p
ATP hydrolysis activity (;100 nmol of Pizmin
21zmg21).
This activity was phospholipid-dependent and sensitive
to low concentrations of vanadate (I50 5 0.3 mM) and
oligomycin (I50 5 8.5 mg/ml).
In vivo, we observed a correlation between the amount
of Yor1p in the plasma membrane and the level of resist-
ance to oligomycin. We also demonstrated that Yor1p
drives an energy-dependent, proton uncoupler-insensi-
tive, cellular extrusion of rhodamine B. Furthermore,
cells lacking both Yor1p and Pdr5p (but not Snq2p)
showed increased accumulation of the fluorescent de-
rivative of 1-myristoyl-2-[6-(NBD)aminocaproyl]phos-
phatidylethanolamine.
Despite their different topologies, both Yor1p and
Pdr5p mediated the ATP-dependent translocation of
similar drugs and phospholipids across the yeast cell
membrane. Both ABC transporters exhibit ATP hydrol-
ysis in vitro, but Pdr5p ATPase activity is about 15 times
higher than that of Yor1p, which may indicate mecha-
nistic or regulatory differences between the two
enzymes.
The yeast YOR11 gene confers oligomycin resistance on over-
expression in a 2-mm plasmid (1). Its nucleotide sequence re-
veals an ORF of 1477 amino acids encoding an ABC protein
highly homologous to mammalian transporters such as the
multidrug resistance-conferring enzyme MRP (BLAST (see
Ref. 2) sequence homology score: p 5 e2228), the organic anion
transporter cMOAT (p 5 e2216), the sulfonylurea receptor (p 5
e2164), and the cystic fibrosis transmembrane conductance reg-
ulator CFTR (p 5 e2132). Yor1p is a “full-size” ABC transporter
with the topology (TM-NBF)2 (3, 4). It consists of two homolo-
gous halves, with each containing a putative ATP-binding do-
main (NBF) and a transmembrane domain of six membrane
spans (TM). Cui et al. (5) showed that Yor1p confers resistance
to a series of drugs including reveromycin A and suggested that
Yor1p may be involved in the cellular efflux of organic anions
including the fluorescent dye rhodamine B. They also showed
that incubation with reveromycin A increases the YOR1 mRNA
level. The transcription of YOR1 is controlled by the homolo-
gous pair of transcription factors Pdr1p/Pdr3p. The level of
YOR1 transcription is decreased by the deletion of either PDR1
or PDR3 and increased in the presence of the gain-of-function
PDR1 alleles (1).
In this paper, we have investigated the transport activity of
Yor1p. Building on previous studies, which indicated that the
(TM-NBF)2-type Yor1p, together with the (NBF-TM)2-type
Pdr5p and Snq2p ABC transporters, are overexpressed in the
PDR1–3 mutant plasma membrane (6–8), the PDR1–3 mutant
has been used as a tool that enhances the Yor1p protein level.
As another investigative tool, we constructed a set of isogenic
strains, in the PDR1–3 mutant, with multiple deletions of
homologous ABC genes since, in situations where two or more
proteins located in the same subcellular compartment share a
common substrate, a clear phenotype is only seen when all the
corresponding genes are deleted, as illustrated by the work of
Mahé et al. (9), who showed that Pdr5p and Snq2p have an
overlapping transport capacity for steroids. We deleted the
yeast ABC transporter-encoding genes known or suspected to
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be controlled by the transcription factors Pdr1p and Pdr3p. The
YCF1 gene, which encodes a glutathione S-conjugate pump
(10), was also deleted. The multiply deleted mutants have
allowed the demonstration that Yor1p and Pdr5p share several
substrates, which include fluorescent phosphatidylethanol-
amine, rhodamine B, and oligomycin, even though previous
studies had concluded that Pdr5p was not involved in oligomy-
cin resistance (11, 12). The pumping of phospholipids is in line
with reports of “flippase” activity with several human and
mouse ABC transporters (13–16). It is also in agreement with
the defective phospholipid accumulation of two new mutant
yeast alleles, PDR1–11 and pdr3–11 (17). Construction of a
stronger Yor1p-overexpressing strain allowed us to detect van-
adate- and oligomycin-sensitive ATPase activity associated
with Yor1p while no UTPase activity was detectable. Despite
similar nucleotide binding specificities and transport capacities
for Yor1p and Pdr5p, the Yor1p enzyme showed 15 times lower
levels of ATP hydrolysis rate than Pdr5p.
EXPERIMENTAL PROCEDURES
Chemicals—n-Dodecyl b-D-maltoside was purchased from
Boehringer Mannheim; bovine serum albumin, 2-deoxy-D-glucose, and
oligomycin were from Sigma; o-nitrophenyl-b-D-galactopyranoside and
rhodamine B were from Merck; molecular weight markers (range
53,000–212,000 Da) and Taq polymerase were from Amersham Phar-
macia Biotech; yeast extract was purchased from both KAT and Difco.
M-C6-NBD-PE, dioleoylphosphatidylcholine, and N-rhodamine-di-
oleoylphosphatidylethanolamine were from Avanti Polar Lipids Inc.
(Alabaster, AL). TNP-8-azido-ATP and the g-32P species were synthe-
sized as described previously (18, 19). All other reagents were of ana-
lytical grade.
Yeast Strains—The Saccharomyces cerevisiae strains used in this
study are listed in Table I. Multiple deletions were performed sequen-
tially in the US50–18C PDR1–3 strain by repeated use of the hisG-
URA3-hisG cassette followed by selection of the ura3 auxotrophic
marker with 5-fluoroorotic acid (20). The plasmids for the deletion of
PDR5 (12), SNQ2, and YOR1 (1) genes were kindly provided by W. S.
Moye-Rowley (Department of Physiology and Biophysics, University of
Iowa, Iowa City, IA). For the deletion of PDR10, PDR11, PDR15, PDR3,
and YCF1 genes, we amplified fragments of the promoter and the ORF
39-end of each gene (Table II). The gene promoters were cloned into the
EcoRI/BamHI sites of pSK, the ORF ends were cloned into the BamHI/
XbaI sites (except for the PDR11 gene; see Table II), and the BamHI/
BglII hisG-URA3-hisG cassette was cloned into the BamHI site.
Linearized fragments of the plasmids were used to transform the
yeast for deletion of PDR5 (BamHI, SalI), SNQ2 (SstI, SalI), YOR1
(SacII/BamHI), PDR10 (EcoRI/NotI), PDR11 (KpnI/NotI), PDR15
(EcoRI/NotI), YCF1 (EcoRI/NotI), and PDR3 (EcoRI/NotI). The deletion
of PDR5, SNQ2, and YOR1 genes was checked by Southern blotting
analysis. Deletion of the other genes was checked by PCR screening:
yeast cells from a 1.5-ml overnight rich glucose medium (YD: 2% yeast
extract, 5.8% glucose) culture were washed, resuspended in 200 ml of 10
mM Tris-HCl, pH 8.0, 100 mM NaCl, and 1 mM EDTA and broken by
vortexing for 2 min with glass beads and 300 ml of phenol-chloroform
(50:50). After a second phenol-chloroform extraction and a washing
with 1 volume of ether, 2 ml of cell extract were used for the PCR
analysis. Recovery of the ura3 marker was monitored by plating onto
5-fluoroorotic acid 107 cells of an overnight YD culture. The resistant
cells were screened by PCR as described above. The deletions of PDR5,
SNQ2, and YOR1 were monitored by Southern analysis.
The SUPERYOR strain was constructed as follows: 1129 bp of the
PDR5 promoter (from position 21141 to 212) and 505 bp of the PDR5
ORF end (from 14026 to 14531) were amplified by PCR using the
following primer sequences: 59-CCATCGATGGTCCGTCATATACG and
59-CCCCCGGGTCTTTCGAACGAGCG (promoter) and 9-CCCCCGGG-
TCTGCTTGTCATTTC and 59-GCTCTAGACTTGGAGAGTTTACC
(ORF end) to which restriction sites had been added (underlined sequ-
ences). The PCR fragments were cut by either ClaI and SmaI (PDR5
promoter) or XbaI and SmaI (PDR5 end) and cloned into ClaI-XbaI-c-
leaved pSK (pSK::PDR5PROM-PDR5STOP). The YOR1 DNA was
prepared as follows. the pEGH452 cosmid (kind gift of Hervé Tettelin)
containing 35.4 kb of S. cerevisiae chromosome VII was cut by MluI. The
5.7-kb fragment, containing the YOR1 ORF, was blunted with Klenow
TABLE I
Yeast strains used in this study
Strains Genotype Reference
IL125–2B MATa, PDR1, his1, parental of the DRI9-T8 PDR1–3 mutant Balzi et al. (24)
2229–5C MATa, PDR1, ura3 Balzi et al. (24)
US50–18C MATa, PDR1–3, ura3, his1, obtained by cross between DRI9-T8 and 2229–5C Balzi et al. (24)
D1–3/3 US50–18C disrupted by Dpdr1::URA3 Balzi et al. (24)
AD1a Dyor1::hisG This study
AD2a Dsnq2::hisG This study
AD3a Dpdr5::hisG This study
AD4a Dpdr10::hisG This study
AD5a Dpdr11::hisG This study
AD6a Dycf1::hisG This study
AD12a Dyor1::hisG, Dsnq2::hisG This study
AD23a Dsnq2::hisG, Dpdr5::hisG This study
AD13a Dyor1::hisG, Dpdr5::hisG This study
AD123a Dyor1::hisG, Dsnq2::hisG, Dpdr5::hisG This study
AD1234a Dyor1::hisG, Dsnq2::hisG, Dpdr5::hisG, Dpdr10::hisG This study
AD23456a Dsnq2::hisG, Dpdr5::hisG, Dpdr10::hisG, Dpdr11::hisG, Dycf1::hisG This study
AD123456a Dyor1::hisG, Dsnq2::hisG, Dpdr5::hisG, Dpdr10::hisG, Dpdr11::hisG, Dycf1::hisG This study
AD124567a Dyor1::hisG, Dsnq2::hisG, Dpdr10::hisG, Dpdr11::hisG, Dycf1::hisG, Dpdr3::hisG This study
AD234567a Dsnq2::hisG, Dpdr5::hisG, Dpdr10::hisG, Dpdr11::hisG, Dycf1::hisG, Dpdr3::hisG This study
AD1234567a Dyor1::hisG, Dsnq2::hisG, Dpdr5::hisG, Dpdr10::hisG, Dpdr11::hisG, Dycf1::hisG,
Dpdr3::hisG
This study
AD234568a Dsnq2::hisG, Dpdr5::hisG, Dpdr10::hisG, Dpdr11::hisG, Dycf1::hisG,
Dpdr15::hisG
This study
AD1234568a Dyor1::hisG, Dsnq2::hisG, Dpdr5::hisG, Dpdr10::hisG, Dpdr11::hisG, Dycf1::hisG,
Dpdr15::hisG
This study
AD2345678a Dsnq2::hisG, Dpdr5::hisG, Dpdr10::hisG, Dpdr11::hisG, Dycf1::hisG,
Dpdr3::hisG, Dpdr15::hisG
This study
AD12345678a Dyor1::hisG, Dsnq2::hisG, Dpdr5::hisG, Dpdr10::hisG, Dpdr11::hisG, Dycf1::hisG,
Dpdr3::hisG, Dpdr15::hisG
This study
SUPERYORa Dyor1::hisG, Dsnq2::hisG, Dpdr5::PDR5PROM-YOR1-PDR5STOP, Dpdr10::hisG,
Dpdr11::hisG, Dycf1::hisG, Dpdr3::hisG
This study
FY1679–28C MATa, PDR1, PDR3, ura3–52, trp1, leu2-D1, his3-D200, GAL2 C. Fairhead, B. Dujon
FY1679–28C/EC FY1679–28C disrupted by Dpdr1::TRP1 Delaveau et al. (44)
FY1679–28C/TD FY1679–28C disrupted by Dpdr3::HIS3 Delaveau et al. (44)
FY1679–28C/TDEC FY1679–28C/TD disrupted by Dpdr1::TRP1 Delaveau et al. (44)
a In this study, the deletions have been done in the PDR1–3 US50–18C strain.


























and cloned into EcoRV-cleaved pSK. The pSK::YOR1 plasmid was cut
by NheI and SnaBI to generate a 5-kb fragment, which was purified,
blunted with Klenow, and cloned into SmaI-cleaved-pSK::
PDR5PROM-PDR5STOP. The pSK::PDR5PROM-YOR1-PDR5STOP
resulting plasmid was cut by ClaI and NotI and used to transform the
AD124567 strain. The transformed yeasts were plated on 0.75 mg/ml
oligomycin. Replacement of the PDR5 chromosomic allele by the mod-
ified YOR1 gene was checked by PCR using primer sequences
corresponding to both the YOR1 and the PDR5 ORFs.
Transcriptional Activity of the Yeast ABC Genes—Transcriptional
activity of the yeast ABC genes was measured after transformation of
the FY1679–28C/EC (pdr1D) strain with 2 centromeric plasmids. The
first plasmid carries either no allele (pRS315), or the wild type
(pRS315::PDR1), or the mutant allele (pRS315::PDR1–3) of the PDR1
gene as described previously (21). The second plasmid (pSEYC102)
bears a translational fusion of the ABC gene promoters and the Esch-
erichia coli lacZ gene. The PDR5-lacZ fusion (12), the SNQ2-lacZ fusion
(8), and the YOR1-lacZ construct (1) have been described previously.
For the construction of the PDR11-lacZ fusion, 687 bp of the PDR11
gene, including 633 bp of the promoter, were amplified by PCR using
the primers 59-CGGGATCCCGATCAAAGGTGACTGAAGC and 59-
GGAATTCCACTTTGACGCCCCTTTATGC (restriction sites are under-
lined). The PCR-amplified promoter was cloned into a BamHI-EcoRI-
cleaved pSEYC102 vector. The same strategy was used to clone 680 bp
of the PDR10 promoter using the primer sequences: 59-GGAATTCCT-
GCCTGACTTACAGATAC and 59-CGGGATCCCACATCCTAACAAC-
TATG and 952 bp of the PDR15 gene, including 897 bp of the promoter,
with the primer sequences: 59-GGAATTCCGCCCAGCCTTTTATACCT
and 59-CGGGATCCCTTGAGCTCGAGCTCCG. b-Galactosidase activ-
ity was measured as described by Sambrook et al. (22) on cell extracts
from yeast grown in synthetic complete glucose medium (SDC: 0.7%
yeast nitrogen base, 2% glucose, complete amino acid supplements)
lacking uracil and leucine.
Complementation of Deleted yor1 Strains by the YOR1 Gene on a
Centromeric Plasmid—The pEGH452 cosmid was cut by MluI. The
5.7-kb restriction fragment containing YOR1, 0.4 kb of the gene pro-
moter including the Pdr1p/Pdr3p binding site, and 0.9 kb downstream
of the STOP codon was blunted with Klenow, cloned into the SmaI site
of pRS316 (pRS316::YOR1) and used to transform the AD13 and
AD1234568 strains for testing complementation of oligomycin and rho-
damine B resistance on plates.
Isolation of Plasma Membranes—Plasma membranes were isolated
from the particulate fraction pelleted at 15,000 3 g for 40 min after
selective precipitation of mitochondria at pH 5.2 (23).
Solubilization of Plasma Membrane Proteins and Centrifugation on a
Continuous Sucrose Gradient—AD1234567 and SUPERYOR plasma
membrane proteins (5 mg/ml) were solubilized with 0.2% (w/v) n-dode-
cyl-b-D-maltoside in the presence of 8 mM Tris-HCl, pH 7.5 (7) and the
solubilized proteins (7 mg) were separated on a 33.3-ml linear sucrose
gradient as described previously (8).
Nucleoside Triphosphatase Assays—Nucleotide hydrolysis of plasma
membrane-enriched fractions was measured by incubation at 35 °C in a
final volume of 100 ml containing 6 mM NTP, 7 mM MgSO4, 10 mM NaN3,
50 mM MES, 50 mM MOPS, and 50 mM Tris, adjusted to the right pH
with either HCl or NaOH. In the sucrose gradient fractions, the NTP
hydrolysis was measured in the presence of 6 mM NTP, 7 mM MgCl2, 50
mM MES, 50 mM MOPS, 50 mM Tris (pH adjusted with either HCl or
NaOH) and 150 mg/ml asolectin. Assays were carried out as described
previously (7).
Photolabeling—Plasma membrane preparations (0.075 or 0.15 mg/
ml) in 25 mM MES/tetramethyl ammonium hydroxide, pH 6.0, 1 mM
MgCl2, 5 mM EGTA, and 20% (v/v) glycerol, containing the indicated
amount of [g-32P]TNP-8-azido-ATP and ATP were photolabeled using a
xenon lamp and toluene filters as described previously (18). The sam-
ples were processed, subjected to SDS-PAGE and autoradiography, and
the radioactivity quantitated by imaging (19).
Drug Resistance Assays—The strains were tested for drug resistance
on solid medium containing 1% yeast extract (Difco) and either 2%
glucose and rhodamine B, or 4% glycerol and oligomycin dissolved in
ethanol. Drug resistance assays after yeast transformation with the
YOR1 gene-containing plasmid were performed on solid synthetic me-
dia containing either 2% glucose or 4% glycerol plus 0.7% yeast nitrogen
base supplemented with amino acids lacking uracil. A 32-well replicator
was used for plating and drug resistance was scored after 3–4 days at
30 °C as described previously (24, 25).
Rhodamine B Fluorescence Measurements in Intact Cells—Four-ml
YD cultures were inoculated with ;50 3 106 cells from an overnight
preculture and incubated for 3 h at 30 °C. Culture aliquots of 750 ml
(;40 3 106 cells/ml) were washed three times with buffer A (50 mM
Hepes-NaOH, pH 7.0), resuspended in 2 ml of buffer A containing 100
mg/ml rhodamine B and either 5 mM D-glucose or 5 mM 2-deoxy-D-
glucose and incubated for 2 h at 28–30 °C. A 1.5-ml sample was pelleted
and washed three times with buffer A. The cell pellet resuspended in
800 ml of water was maintained on ice until cell fluorescence was
measured using an SLM Aminco 48000 S spectrofluorimeter. The exci-
tation wavelength was 555 nm (slit of 4 nm), and the emission wave-
length was 575 nm (slit of 4 nm).
In rhodamine B extrusion experiments, cells from 3.5 ml of YD
culture (;40 3 106 cells/ml) were washed three times with buffer A,
incubated in 2 ml of buffer A containing 100 mg/ml rhodamine B and 5
mM 2-deoxy-D-glucose for 2 h at 28–30 °C and then washed three times
with buffer A and resuspended in 1.5 ml of buffer A. Rhodamine B
extrusion was measured in response to either 10 mM D-glucose, 4%
ethanol, or no carbon source (control). At the indicated times, the
fluorescence of 300 ml of both the cell-free supernatant and the cell
pellet were measured.
Yeast Cell Labeling with NBD-phosphatidylethanolamine—Lipid
vesicles including 50 mM total lipids comprising M-C6-NBD-PE (40
mol%), dioleoylphosphatidylcholine (58 mol%), and N-rhodamine-dio-
leoylphosphatidylethanolamine (2 mol%) were prepared as described
previously (17). Phospholipid concentrations were determined by the
lipid phosphorus assay (26). For internalization of M-C6-NBD-PE, yeast
cells were grown overnight in SDC at 30 °C, diluted, and allowed to
grow to an A600 of 0.2–0.3. Donor vesicles containing the fluorescent
lipids were added to the yeast cells and incubated for 30 min at 37 °C.
Cells were washed three times with ice-cold SCNaN3 (SDC lacking
glucose but containing 2% sorbitol and 20 mM sodium azide) prior to
analysis by fluorescence microscopy and flow cytometry.
Fluorescence Microscopy—Fluorescence microscopy was performed
on a Zeiss Axiovert microscope equipped with barrier filters that al-
lowed no detectable crossover of NBD and rhodamine fluorescence. The
fluorescence image was enhanced with a VE1000-SIT image-intensify-
TABLE II
PCR amplifications for disruption constructs
Gene First primera,b Second primer Restrictionsitesb Size
c
bp
PDR10 P: 59-GGAATTCCTGCCTGACTTACAGATAC 59-CGGGATCCCGAGTTTGAACTTGAGGGC EcoRI/BamHI 709
S: 59-CGGGATCCCGGTCAAATGAGGAGCAGAAG 59-GCTCTAGAGCATCCATCTACGTGAATACG BamHI/XbaI 912
PDR15 P: 59-GGAATTCCGCCCAGCCTTTTATACCT 59-CGGGATCCCTTGAGCTCGAGCTCCG EcoRI/BamHI 952
S: 59-CGGGATCCCGGAGGTTGTAGGTGCCG 59-GCTCTAGAGCCACACCAAGGGCTAAT BamHI/XbaI 845
PDR11 P: 59-GCTCTAGAGCCAGCCAAAATAGCGTCAAAT 59-CGGGATCCCGAACGAAAACGGACGGAGAAG XbaI/BamHI 970
S: 59-GGAATTCCGCAGACGGTGTATGTGTT 59-CGGAATTCCGAAAAGAGGTGGTGAGTGTGT EcoRI/EcoRI 1137
YCF1 P: 59-CGGGATCCCGCCCTTCAGGAGATCTACA 59-GGAATTCCATTCATGTATGATCTCCAG EcoRI/BamHI 827
S: 59-CGGGATCCCGGTCGTTTAGACTCTATTAC 59-GCTCTAGAGCCGATGGTCAAGATAGTTC BamHI/XbaI 1041
PDR3 P: 59-CGGGATCCCGCACTTTCATTGCGGTC 59-GGAATTCCGGGCTTGGATACCTTCGC EcoRI/BamHI 523
S: 59-CGGGATCCCGCATCTTGGGTGCTGTT 59-GCTCTAGAGCCACTGCTGACAAACTC BamHI/XbaI 907
a The primer sequences for the PCR amplifications were chosen in the promoter (P) and in the ORF 39-end (S) sequence of each gene.
b Restriction sites were added for the cloning (underlined sequences).
c Size of the PCR-amplified DNA fragments.


























ing camera (DAGE-MTI Inc., Michigan City, IN), digitized, and stored.
Image manipulation and editing were performed with Metamorph soft-
ware (Universal Imaging Corp., West Chester, PA).
Flow Cytometry—Flow cytometric analysis of the M-C6-NBD-PE la-
beled cells was performed with a FACScan cytometer (Becton-Dickin-
son Immunocytochemistry, San Jose, CA) equipped with an argon laser
operating at 488 nm. Ten ml of a 50 mg/ml stock solution of propidium
iodide was added to approximately 4 3 105 cells in 200 ml of SCNaN3
immediately prior to dilution (;3 times) and flow cytometric analysis.
Ten thousand cells were analyzed without gating during acquisition.
Analysis was performed with Lysis II (Becton-Dickinson Immunocyto-
chemistry Systems) software. A dot plot of forward scatter versus the
red fluorescence channel (propidium iodide) was used to set a gate that
excluded dead cells from the analysis. The remaining live cells were
plotted on a histogram with the green fluorescence (M-C6-NBD-PE)
plotted on a log scale, and the mean (Fcell) and standard deviation of the
fluorescence intensity of the live cells calculated.
Other Methods—The protein content was measured as described by
Lowry et al. (27) with bovine serum albumin as the standard. The
protein samples were electrophoresed on SDS-polyacrylamide gel ac-
cording to Laemmli (28) and stained with either Coomassie Blue or
silver. The yeast cells were transformed as described by Kuo and
Campbell (29), and bacteria (DH5a strain) transformation was per-
formed by electroporation using a Bio-Rad Gene Pulser apparatus,
following the manufacturer’s instructions.
RESULTS
Overexpression of Yor1p and Genetic Purification—The low
level of expression of YOR1 in wild-type yeast (1) precludes
characterization of its properties. Traditional overexpression of
plasma membrane proteins using strong promoters and multi-
copy vectors often causes mistargeting and stimulates accumu-
lation of intracellular membranes (30). These problems have
been overcome in a new approach, which has allowed dramat-
ically enhanced overexpression of Pdr5p and Snq2p ABC trans-
porters in the yeast plasma membrane (6–8). The method
takes advantage of point mutations in the transcription factor-
encoding genes PDR1/PDR3, which activate the transcription
of their target genes. The target gene promoters contain typical
binding sequences called PDREs (for PDR response elements)
which correspond to the 59-TCCG(C/T)GGA-39 consensus se-
quence (12, 31, 32) (Table III). An inherent problem to this
approach is the simultaneous overexpression of several Pdr1p-
regulated proteins, including other ABC transporters. It was
therefore necessary to identify all potentially interfering pro-
teins and eliminate them by gene deletion. Systematic sequenc-
ing of the yeast genome has revealed new ORFs, which encode
a total of 15 full-size ABC transporters (3) including the PDR10
(33), PDR15 (34), and PDR11 (35) genes whose promoters dis-
play at least one putative PDRE. Table III shows the transcrip-
tion activity mediated by the PDR5, YOR1, SNQ2, PDR10,
PDR15, and PDR11 promoters in the presence of PDR1 wild
type-, null, or mutated PDR1–3 allele as measured by the
b-galactosidase activity of fusion constructs. The PDR11 pro-
moter-mediated transcription activity was weak and not sig-
nificantly affected by Pdr1p, possibly because the 59-TCCG-
CAGA-39 sequence in the promoter was insufficient for Pdr1p/
Pdr3p recognition. The PDR1–3 mutation slightly increased
the efficiency of the PDR15 gene promoter despite the presence
of a perfect Pdr1p/Pdr3p-binding site. In contrast, the PDR1–3
allele increased the efficiency of the PDR10 promoter 11-fold.
Note, however, that the putative PDREs of the PDR10, PDR15
and PDR11 gene promoters have yet to be verified experimen-
tally. In the presence of the wild-type allele of PDR3, the
PDR1–3 mutation increased expression of b-galactosidase 25
times for the YOR1 promoter, 17 times for the PDR5 promoter,
and 5 times for the SNQ2 promoter.
Table III also shows that the number of putative PDREs per
promoter did not correlate with the extent of the induction of
b-galactosidase activity mediated by Pdr1p. Although the
PDR5 and SNQ2 promoters each have three PDREs (12, 31,
32), PDR5-lacZ expression was enhanced 5 times by the wild-
type Pdr1p while the expression of the SNQ2-lacZ fusion was
increased only 1.4 times upon the addition of the wild-type
PDR1 allele. Under the same conditions, the induction of the
other translational lacZ fusions showing 1 or 2 putative PDREs
varied between 1.4 (YOR1-lacZ) and 2.2 (PDR10-lacZ). A fur-
ther important point is that the b-galactosidase activities of
PDR5-, SNQ2-, and YOR1-lacZ fusions reported here in the
presence of wild type Pdr3p are quite different to when Pdr3p
is absent (21).
In agreement with the results of Table III, Fig. 1 shows that
the PDR1–3 mutant plasma membrane (compared with that
from either wild type or pdr1D strains) dramatically overex-
pressed a 160-kDa Coomassie Blue-stained band, which mainly
comprised Pdr5p, Snq2p, and Yor1p. In order to free Yor1p
from membrane contaminants of similar size and possibly over-
lapping function, we deleted PDR5, SNQ2, PDR10, and PDR15
yeast ABC transporter-encoding genes whose expression was
also induced by the PDR1–3 mutation. The PDR11 gene whose
product is a constituent of the 160-kDa overexpressed band (8)
was also deleted. YCF1 was deleted because this gene is in-
volved in drug resistance (36, 37).
Yor1p Binds TNP-8-azido-ATP and Shows ATPase
Activity—Using the AD234567 multiply deleted strain overex-
pressing Yor1p, we started to investigate the Yor1p potential
NTP hydrolysis activity. Pdr5p has an NTPase activity, which
was distinguished from that of the H1-pump Pma1p by its
TABLE III
Measurement of PDR5, YOR1, SNQ2, PDR10, PDR15, and PDR11 transcription activity mediated by pdr1D, PDR1, and PDR1–3 alleles
Pdr1/3p-binding consensusa pRS315b pRS315::PDR1 pRS315::PDR1–3
PDR5-lacZ 2492TTCCGCGGAA2483 29.2 6 3 147 6 48 2473 6 550
2376TTCCGTGGAA2367
2314CTCCGCGGAA2305
YOR1-lacZ 2402TTCCACGGAA2393 15.6 6 7 21.5 6 11 530 6 119
SNQ2-lacZ 2602ATCCGCGGAG2593 45.5 6 7.5 61.5 6 3 301 6 55
2581TTCCGCGGAT2572
2543TTCCGCGCAC2534
PDR10-lacZ 2408CTCCGTGGAA2399 0.16 6 0.07 0.36 6 0.05 4.1 6 1.9
2339TTCCACGGAC2330
PDR15-lacZ 2443TTCCGCGGGA2434 2.4 6 0.5 4.1 6 1.3 6.0 6 2.8
2380TTCCGCGGAG2371
PDR11-lacZ 2205TTCCGCAGAT2196 0.21 6 0.04 0.28 6 0.06 0.18 6 0.03
a The conserved residues of Pdr1/3p binding motifs found in the promoter regions of the genes are shown in boldface type, and the palindromic
sequences are underlined.
b The measurements were done in the FY1679/EC (pdr1D) strain as described under “Experimental Procedures.” The b-galactosidase activities,
measured in four independent yeast transformants, are expressed with the standard errors.


























broader nucleotide specificity and pH dependence (7, 8). With
similar protein levels in the plasma membrane, the UTPase
activity of Pdr5p was up to 10-fold higher than that of Pma1p
(Fig. 2), which is the major ATPase in the yeast plasma mem-
brane. The situation with Yor1p-enriched plasma membrane
(AD234567) was very different since no significant difference in
the NTPase activity was detected compared with the Yor1p-
depleted strain (AD1234567). The same results were obtained
with the AD2345678/AD12345678 strains. However, in the SU-
PERYOR strain obtained by fusion of the PDR5 promoter to the
YOR1 ORF, a survey of pH from 5.0 to 8.5 revealed that some
very low ATPase activity could be associated with SuperYor1p
above pH 7.0 (data not shown).
Partial purification of SuperYor1p by centrifugation on su-
crose gradient, separated it from H1-ATPase (Fig. 3A). This
allowed us to detect ATPase activity associated with the
SuperYor1p-enriched fractions (fractions 6–12) after subtrac-
tion of the contaminating ATPase activity (;75 nmol of
Pizmin
21zmg21) measured in the corresponding fractions of the
AD1234567 Yor1p-depleted strain (Fig. 3B). Detection of the
ATPase activity required the presence of 150 mg/ml asolectin,
which was found to be optimal concentration (data not shown).
By scanning the SDS-polyacrylamide gel, we found good corre-
lation between the SuperYor1p band intensity and its ATPase
activity (Fig. 3B). The enzyme was able to hydrolyze ATP from
pH 7.0 to 8.5 with similar efficiency (Fig. 3C). ATPase activity
was strongly sensitive to vanadate (I50 ; 0.3 mM) and inhibited
by oligomycin concentrations above 3 mg/ml (Fig. 3, D and E).
Recently, the fluorescent ATP analogue, TNP-ATP, was
shown to bind tightly to several proteins including the purified
recombinant NBD1 and NBD2 of mouse MDR P-glycoprotein
(38, 39), a synthetic NBD1 of human CFTR (40), and the
Chinese hamster P-glycoprotein (41). Photolabeling of plasma
membranes enriched in Yor1p (AD234567) and Pdr5p
(AD124567) with [g-32P]TNP-8-azido-ATP is shown in Fig. 4A.
The labeling of Pma1p is given for comparison. The two ABC
transporters exhibited a very similar dependence on nucleotide
concentration for photolabeling (K0.5 5 45 and 46 mM for Yor1p
and Pdr5p, respectively), whereas Pma1p required a slightly
FIG. 2. The level of Yor1p in the plasma membrane is enhanced
by fusing the PDR5 promoter to the YOR1 ORF. One hundred mg
of plasma membrane-enriched fractions were separated onto 7%-SDS-
PAGE and stained with Coomassie Blue. From left to right: AD1234567
(yor1D, snq2D, pdr5D, pdr10D, pdr11D, ycf1D, pdr3D), AD234567
(snq2D, pdr5D, pdr10D, pdr11D, ycf1D, pdr3D), SUPERYOR (yor1D,
snq2D, Dpdr5::PDR5PROM-YOR1-PDR5STOP, pdr10D, pdr11D, ycf1D,
pdr3D), AD124567 (yor1D, snq2D, pdr10D, pdr11D, ycf1D, pdr3D). The
nature of the 160-kDa overexpressed protein is given in each case. The
maximum non-inhibitory concentrations of drug for growth on either
oligomycin or cycloheximide are shown. We could not determine the
corresponding oligomycin concentration for the SUPERYOR strain be-
cause of its poor solubility in rich glycerol medium (YG: 2% yeast
extract, 4% glycerol) plates. The UTPase activities of the plasma mem-
brane-enriched fractions at pH 6.3 are given in the last row.
FIG. 1. Pdr5p, Snq2p, and Yor1p are
overexpressed in the PDR1–3 mutant
plasma membrane. Plasma membrane-
enriched fractions were separated onto
7–14% SDS-PAGE and stained with Coo-
massie Blue. From left to right: US50–
18C (PDR1–3), AD3 (PDR1–3, pdr5D),
AD23 (PDR1–3, pdr5D, snq2D), AD123
(PDR1–3, pdr5D, snq2D, yor1D), 2229–5C
(PDR1), and D1–3/3 (pdr1D). Each lane
contains 150 mg of protein.


























higher concentration range (K0.5 5 93 mM). The effect of com-
petitor ATP on the photolabeling is shown in Fig. 4B. The
concentration of TNP-nucleotide chosen was close to the K0.5
value for the ABC transporters. It has been shown previously
that the labeling reaction in the presence of ATP approximates
an equilibrium situation and the “ true ” dissociation constants
for ATP (KD(ATP)) can be derived from the observed inhibition
curves (K0.5(ATP)) using the equation: KD(ATP) 5 K0.5(ATP)/{1
1 ([TNP-8-azido-ATP]/K0.5(TNP-8-azido-ATP))} (19). The label-
ing of all three pumps is inhibited by ATP in the millimolar
concentration range, yielding KD values of 0.3 mM for both the
ABC transporters and the proton pump. This value is in good
agreement with the Km for activation of proton transport (42).
Note, however, that the TNP-8-azido-ATP binding on Pdr5p
and Yor1p proteins has yet to be verified experimentally.
Overexpressed Yor1p Confers Increased Resistance to Oligo-
mycin in Vivo—Overexpressed Yor1p has been reported to con-
fer resistance to oligomycin (1). The analysis of the multiple
deletions shows that oligomycin resistance of the PDR1–3 mu-
tant strain is also dependent on the presence of Pdr5p. Unlike
AD1 (yor1D) and AD12 (yor1Dsnq2D) strains, the AD13
(yor1Dpdr5D) strain does not grow on plates containing 0.25
mg/ml oligomycin (Fig. 5). Previous studies showed unmodified
oligomycin sensitivity in single PDR5 deletants (11, 12) but
Kolaczkowski et al. (43) showed that oligomycin is a competi-
tive inhibitor of Pdr5p-mediated transport of rhodamine 6G. As
also shown by Fig. 5, Pdr1p more strongly influences oligomy-
cin resistance than its homolog Pdr3p (compare the FY1679/EC
(pdr1D) and FY1679/TD (pdr3D) strains). This is in agreement
with previous observations (12) even though no difference in
oligomycin resistance between pdr1D and pdr3D strains was
observed by Delaveau et al. (44). As also shown by Fig. 2,
oligomycin resistance was increased 40 times in the strain
AD234567 which overexpresses Yor1p and was further in-
creased by a factor of more than 8 in the SUPERYOR strain.
These data indicate that, at the cell level, the drug transport
properties of Yor1p are conserved during overexpression.
Overexpressed Yor1p Confers Resistance to Rhodamine
B—Cui et al. (5) recently found that deletion of YOR1 increases
the cellular content of rhodamine B (which is negatively
charged, unlike the Pdr5p substrate rhodamine 6G; see Ref.
43). Analysis of the multiply deleted mutants revealed that
rhodamine B resistance is mediated by both Yor1p and Pdr5p.
The deletion of PDR5 did not allow cell growth in the presence
of 500 mg/ml rhodamine B and deletion of both PDR5 and YOR1
(AD13) increased drug sensitivity so that the cells fail to grow
in 250 mg/ml rhodamine B (Fig. 5). Finally, the combined dele-
tion of the YOR1, SNQ2, PDR5, PDR10, PDR11, PDR15, and
YCF1 genes (strains AD1234568 and AD12345678) further
reduced the resistance to rhodamine B since growth was di-
minished at 50 mg/ml rhodamine B and abolished at 100 mg/ml
rhodamine B. Pdr1p affects rhodamine B and oligomycin re-
sistance more drastically than Pdr3p (FY1679/EC (pdr1D) com-
pared with FY1679/TD (pdr3D)). Thus, Pdr1p and Pdr3p me-
FIG. 3. Solubilized and partially pu-
rified SuperYor1p hydrolyses ATP.
Solubilized plasma membrane proteins (7
mg) from strains SUPERYOR (yor1D,
snq2D, Dpdr5::PDR5PROM-YOR1-PDR5
STOP, pdr10D, pdr11D, ycf1D, pdr3D)
and AD1234567 (yor1D, snq2D, pdr5D,
pdr10D, pdr11D, ycf1D, pdr3D) (data not
shown) were separated by centrifugation
through a continuous sucrose gradient.
Fifty ml of fractions 4–15 were analyzed
by SDS-PAGE and stained with silver (A).
The polyacrylamide gel was scanned and
the intensity of the SuperYor1p band was
estimated using the Image Master 1D
program (Amersham Pharmacia Biotech)
(B, closed triangles). Ten ml of fractions
4–12 (SUPERYOR gradient) were as-
sayed for ATPase activity at pH 7.5 as
described under “Experimental Proce-
dures” and, each time, the contaminating
ATPase activity measured in the corre-
sponding fractions of the deleted strain
(AD1234567) was subtracted (B, open cir-
cles). The activities were calculated for
three independent gradients of each
strain. Similarly, the effects of pH (C),
vanadate at pH 7.5 (D), and oligomycin at
pH 7.5 (E) on SuperYor1p ATPase activ-
ity were estimated.


























diate rhodamine B and oligomycin resistance through both
Pdr5p and Yor1p. Notice that Yor1p and Pdr5p share other
common substrates, including the fungicide miconazole (data
not shown).
The involvement of Yor1p in rhodamine B and oligomycin
resistance of pdr5D strains was confirmed by complementation
of the AD13 (yor1Dpdr5D) and the AD1234568 (yor1D, snq2D,
pdr5D, pdr10D, pdr11D, ycf1D, pdr15D) strains with the YOR1
gene. Transformation of both strains with the YOR1 gene on
centromeric plasmid allowed recovery of growth on both 0.5
mg/ml oligomycin and 250 mg/ml rhodamine B as shown for the
AD3 and AD234568 strains (data not shown).
The Efflux of Rhodamine B in Yeast Cells Overexpressing
Yor1p Is Energy-dependent—We therefore used the Yor1p-
overexpressing strain AD2345678 (snq2D, pdr5D, pdr10D,
pdr11D, ycf1D, pdr3D, pdr15D) and its isogenic control, deleted
in YOR1, AD12345678 (yor1D, snq2D, pdr5D, pdr10D, pdr11D,
ycf1D, pdr3D, pdr15D) to demonstrate the involvement of Yor1p
in the rhodamine B cell content. In the yor1D strain, rhodamine
B accumulation was slightly lowered (82%) by deoxyglucose
compared with glucose (100%). However, in the presence of
overexpressed Yor1p, rhodamine B accumulation was much
higher (58%) in energy-starved cells (deoxyglucose), while glu-
cose caused a drastic reduction (to 8%) in the cellular rhoda-
mine B content (data not shown). Fig. 6A shows the Yor1p-
mediated energy-dependent extrusion of rhodamine B from
pre-loaded cells incubated with deoxyglucose, which depletes
the intracellular ATP (45). The addition of glucose caused rapid
extrusion of rhodamine B from the Yor1p-expressing cells,
while no glucose-dependent effect was observed in the yor1D
cells. Fig. 6B shows the difference in the supernatant fluores-
cence (Fglucose 2 Fcontrol) in the same experiment and estab-
lishes the Yor1p energy-dependent extrusion of rhodamine B
out of the cell. Addition of 30 mM protonophore FCCP in the
presence of the respiratory substrate ethanol as the sole energy
source completely abolished rhodamine B transport. while, in
FIG. 4. TNP-8N3-ATP photolabels
Yor1p and Pdr5p and the labeling is
inhibited by ATP. Photolabeling was
performed with the concentrations of
[g-32P]TNP-8-azido-ATP shown (A) or
with 45 or 50 mM [g-32P]TNP-8-azido-
ATP, for Yor1p (strain AD234567) or
Pdr5p (AD124567) and Pma1p
(AD124567), respectively, and the concen-
trations of ATP shown (B). Open trian-
gles, Yor1p (AD234567); open circles,
Pdr5p (AD124567); closed circles, Pma1p
(AD124567). In A, the lines show the best
fit to the data. The K0.5(TNP-8-azido-
ATP) values are given in the text. In B,
the line shows the best fit to the data
obtained for Pdr5p and yielded a
K0.5(ATP) of 0.9 mM. That for Yor1p was
similar. The value for Pma1p was 0.6 mM.
The “true” KD values are given in the text.
The insets show autoradiographs of the
relevant gel bands.


























the presence of glucose, FCCP only slightly affected Yor1p-
mediated rhodamine B transport (Fig. 6C). This may be ex-
plained either by the partial involvement of oxidative phospho-
rylation in the ATP formation of glucose-grown cells and/or by
a possibly higher use of cellular ATP by the Pma1p H1-ATPase
under these conditions. In the absence of an energy source, the
application of a pH gradient of 2 units (pH 7.0 inside the cell
and pH 5.0 outside the cell) did not cause rhodamine B extru-
sion (Fig. 6C).
These data indicate that the energy required for drug efflux
FIG. 5. Yor1p and Pdr5p confer in vivo resistance to oligomycin and rhodamine B. For oligomycin resistance tests, cells were spotted
onto YG plates containing either 0, 0.25 or 0.5 mg/ml (C). Resistance to rhodamine B was tested on YD plates containing 100, 250, or 500 mg/ml
(D). Plates were incubated for 3 days at 30 °C. The names of the tested strains are shown in A. B describes the nomenclature used for the PDR1–3
multiply deleted strains.
FIG. 6. Yor1p mediates ATP-dependent efflux of rhodamine B in vivo. Pre-loaded deenergized cells were incubated at 30 °C and the efflux
of rhodamine B was measured after the addition of either 10 mM glucose or 4% ethanol, while no energy source was added in the control fraction.
At the indicated times, cells were pelleted and the fluorescence was measured in both the supernatant and the cell pellet. A, fluorescence of the
cell pellet; closed squares, strain AD2345678 (snq2D, pdr5D, pdr10D, pdr11D, ycf1D, pdr3D, pdr15D) 1 glucose; open squares, AD2345678 control;
closed circles, strain AD12345678 (yor1D, snq2D, pdr5D, pdr10D, pdr11D, ycf1D, pdr3D, pdr15D) 1 glucose; open circles, AD12345678 control. B,
difference between the supernatant fluorescence after addition of glucose (FSN glucose) and in the control fraction (FSN control); closed squares,
strain AD2345678; open circles, strain AD12345678. C, fluorescence of the cell pellet in the AD2345678 strain; closed squares, glucose; closed
circles, ethanol; open circles, glucose 1 30 mM FCCP; closed triangles, ethanol 1 30 mM FCCP; open squares, pH gradient (pH 7.0 inside the cell and
pH 5.0 outside). The bars represent the standard deviations.


























by Yor1p is not provided by the proton motive force across the
plasma membrane. This is in agreement with previous studies
showing the ATP requirement for drug transport by several
other ABC transporters, including the yeast Pdr5p (43) and
Ycf1p (10), the lactococcal MDR transporter (46), and the mam-
malian MRP (47) and MDR1 (48).
Yor1p and Pdr5p Are Involved in M-C6-NBD-phosphati-
dylethanolamine Accumulation in Vivo—Several mammalian
ABC transporters translocate phospholipids (13–16). A “flip-
flop” of hydrophobic drugs from the inner leaflet to the outer
one has been proposed as part of the mechanism of drug trans-
port (49). We have tested whether overexpressed Yor1p was
involved in the transport of a fluorescent phospholipid analog,
M-C6-NBD-PE. Cell fluorescence was measured by flow cytom-
etry after the incubation of yeast cells with M-C6-NBD-PE (Fig.
7A) and analyzed by fluorescence microscopy (Fig. 7B). The
average accumulation of M-C6-NBD-PE in the PDR1–3 mutant
strain (US50–18C) was about 13% of the PDR1 parent strains
(IL125–2B and 2229–5C). In similar experiments, another mu-
tant, PDR1–11, accumulated 1–2% of its isogenic parent.2 A
strain in which the PDR1 gene was deleted (D1–3/3) accumu-
lated about 70% more M-C6-NBD-PE than the PDR1 parent
strains (Fig. 7A). It therefore seems likely that Pdr1p activates
the expression of genes encoding proteins that decrease the
steady-state accumulation of M-C6-NBD-PE by either increas-
ing its efflux or decreasing its influx.
Thus, to determine if any of the seven ABC transporters
included in this study were responsible for the efflux of M-C6-
NBD-PE, we analyzed the multiply deleted strains. Based on
the average M-C6-NBD-PE fluorescence intensity for 10,000
cells, the PDR1–3 strain accumulated only 8% of the pdr1D
strain. Deletion of YOR1 (AD1) or PDR5 (AD3) in the PDR1–3
strain resulted in an increase to 13% M-C6-NBD-PE accumu-
lation. The fluorescence intensity of the doubly deleted strain
yor1D pdr5D (AD13), was increased to 36% of the pdr1D strain
(60% of the PDR1 wild-type strain), a value slightly higher
than if the two effects were additive. Single deletions of SNQ2
(AD2), PDR10 (AD4), PDR11 (AD5), YCF1 (AD6), or PDR15
(AD8) had no effect on M-C6-NBD-PE accumulation. Thus, of
the ABC transporters tested, only Pdr5p and Yor1p appeared
to transport M-C6-NBD-PE.
DISCUSSION
This study provides some new information on the control of
YOR1 and other yeast ABC genes by the transcription factors
Pdr1p and Pdr3p. The expression of lacZ gene fusions with
PDR10, PDR15, and PDR11 gene promoters containing puta-
tive PDREs reveals that PDR10 may be a target of Pdr1p/
Pdr3p transcription factors. However, its level of expression
was very low compared with that of PDR5, SNQ2, and YOR1,
whose transcription was greatly enhanced by the PDR1–3 mu-
tation. Transcription of the PDR15 gene, despite the presence
of one perfect Pdr1p/Pdr3p-binding site (PDRE) in its pro-
moter, was only increased 2 fold by the PDR1–3 mutation. The
transcription level of the PDR11 gene was not modified upon
addition of either the wild type PDR1 or the mutated PDR1–3
allele, possibly because the PDRE sequence in its promoter is
not sufficient for Pdr1p/Pdr3p binding (TCCGCAGA instead of
TCCG(T/C)GGA).
In the PDR1–3 gain-of-function mutant, the PDR5 gene pro-
moter gave the highest absolute b-galactosidase activity among
the fusion products with five different Pdr1p-regulated gene
promoters. This is consistent with the SDS-PAGE analysis of
plasma membrane-enriched fractions of multiply deleted
strains. The latter analysis also confirmed that Pdr5p, Snq2p,
and Yor1p ABC transporters are the major components of the
160-kDa overexpressed protein band in the PDR1–3 mutant.
Characterization of Yor1p, a minor protein of the plasma
membrane, required both the overexpression of the Yor1p pro-
tein and also the deletion of related ABC transporters, in par-
ticular those suspected to be activated by the PDR1–3 muta-
tion. We were able to delete up to 7 full-size yeast ABC2 A. M. Grant and J. W. Nichols, unpublished observations.
FIG. 7. Yor1p and Pdr5p are involved in M-C6-NBD-PE accu-
mulation in vivo. After M-C6-NBD-PE internalization, cells were sub-
mitted to both flow cytometric analysis and fluorescence microscopy. A,
flow cytometric analysis of the M-C6-NBD-PE-labeled cells. Fcell is the
mean of the fluorescence intensity of a population of ;10,000 live cells.
The bars represent the standard deviations. According to unpaired
Student’s t test, values are statistically different from value for US50–
18C strain with p , 0.01 (§); with p , 0.05 (*); values are not signifi-
cantly different from value for US50–18C strain since p . 0.1 (£). B,
fluorescence microscopy: 5% means that a neutral density filter was
used to reduce the excitatory light by 95%. In the second column (100%),
the filter was removed. The last column shows the differential interfer-
ence contrast optics.


























transporters without impairing growth.
Membrane-bound Yor1p was labeled with TNP-8-azido-ATP
in vitro in a saturable manner and the labeling was inhibited
by ATP. Interestingly, the K0.5 for TNP-8-azido-ATP that we
found for Yor1p (about 45 mM) is very close to the value found
by Liu and Sharom for TNP-ATP binding to human P-glyco-
protein (43 mM) (50). The nucleotide binding properties of Pdr5p
and Yor1p appeared very comparable.
Investigation of the drug transport properties of intact cells
overexpressing Yor1p showed that the Yor1p enzyme was ac-
tive in vivo and required energy. The oligomycin resistance was
increased 40 times in the strain overexpressing Yor1p and
further increased by about 8-fold in the SUPERYOR strain,
indicating that overexpression of Yor1p does not change its
oligomycin transport capability in vivo. Absence of Yor1p or
Pdr5p caused increased sensitivity to both oligomycin and rho-
damine B. These effects were additive when both proteins were
missing. A requirement for energy was demonstrated by the
strong efflux of rhodamine B from Yor1p-enriched energy-
starved cells on glucose addition. The energy required for this
process appears to be provided by ATP rather than DpH. Fi-
nally, absence of either Yor1p or Pdr5p resulted in increased
accumulation of a fluorescent phosphatidylethanolamine.
Again, the effect was more pronounced when both ABC trans-
porters were deleted, indicating that the transporters may act
independently. Conversely, none of the 5 other ABC transport-
ers, including the overexpressed Snq2p transporter, exhibited
this activity.
In plasma membranes from the AD234567 Yor1p-expressing
strain, it was difficult to measure ATPase activity distinct from
that of Pma1p. Enhancing the level of Yor1p by fusing the
YOR1 ORF to the PDR5 promoter in the PDR1–3 mutant
(SUPERYOR strain) allowed us, however, to detect ATPase
activity in solubilized and partially purified SuperYor1p frac-
tions. The SuperYor1p activity of ;100 nmol of Pizmin
21zmg21
was sensitive to both vanadate and oligomycin, establishing
that we are not dealing with either P-type or F-type ATPase
contaminants. The use of the PDR1–3 gain-of-function allele of
PDR1 has already allowed characterization of the Pdr5p and
Snq2p NTPase activities (7, 8). Surprisingly, Pdr5p, Snq2p,
and (Super)Yor1p NTPase activities show distinct characteris-
tics; Pdr5p hydrolyzes all Mg-NTPs over a broad pH range,
whereas Snq2p and Yor1p hydrolyze ATP preferentially. The
pH profile of Yor1p ATPase activity is also very broad (with an
optimum at pH 7.5), while it is much sharper for Snq2p (pH
6.3). Only Pdr5p and Yor1p ATPase activities are oligomycin-
sensitive, while vanadate was shown to inhibit all three en-
zyme ATPase activities. Finally, taking into account the rela-
tive amount of each transporter in the plasma membrane, one
can estimate that the Yor1p ATPase activity is more or less 15
times lower than that of Pdr5p or Snq2p.
As the pumping capacity (and specificity) of the Yor1p and
Pdr5p transporters appears similar in vivo, the low ATPase
activity of Yor1p (;0.1 mmol of Pizmin
21zmg21) compared with
that of Pdr5p (;1.5 mmol of Pizmin
21zmg21) in similar condi-
tions may indicate that the purified Yor1p transporter is a
more highly coupled pump than Pdr5p. The high ATPase ac-
tivity and apparently low pumping capacity of ABC drug trans-
porters (51–54) has been a puzzling feature. For instance,
Pdr5p ATPase activity is very high in the apparent absence of
drugs or other substrates, slightly stimulated by substrates,
and shows a broad nucleotide specificity despite an in vivo
requirement for ATP for transport (43). The poor NTPase ac-
tivity of Yor1p might be due to the fact that an activation factor
required for ATPase activity is lost during the plasma mem-
brane preparation or that some phospholipids block the Yor1p
ATPase activity when tested in membranes. Another possibil-
ity is that Yor1p, like its ortholog CFTR, has low ATPase
activity (;0.05 mmol of Pizmin
21zmg21) that is sufficient for the
control of channel gating (55). Very recently, the close human
ortholog of Yor1p, MRP, was purified and shown to hydrolyze
ATP at a rate of ;0.3 mmol of Pizmin
21zmg21 in the presence of
6 mM Mg-ATP (56). If we consider that, in our preparations, the
“purified” SuperYor1p amounts to 20% of the total proteins,
one can estimate that SuperYor1p may exhibit an ATP hydrol-
ysis rate of ;0.5 mmol of Pizmin
21zmg SuperYor1p21.
The mediation of phospholipid efflux by yeast Pdr5p and
Yor1p is consistent with recent reports that identified other
ABC transporters as phospholipid transporters or flippases.
These include mouse mdr1 (16) and mdr2 (13, 14) and human
MDR1 (16) and MDR3 (15, 16). Phospholipid transport by
MDR1 and mdr1 is not head-group or glycerol backbone-spe-
cific, whereas the MDR3 P-glycoprotein transports phosphati-
dylcholine exclusively. The specificity of Yor1p and Pdr5p for
phospholipids other than phosphatidylethanolamine remains
to be seen, but it could be different for the two pumps. It seems
possible that the high steady state of ATP hydrolysis by Pdr5p
and the low ATPase activity of Yor1p may be related to acti-
vation of the former with certain yeast phospholipids, which
may not be substrates or even inhibitors of the latter. Anyway,
it is intriguing that Pdr5p and Yor1p share similar phospho-
lipid translocation properties which were not observed for
Snq2p.
Finally, we wish to point out that, taking advantage of the
strong PDR5 promoter associated with the gain-of-function
PDR1–3 mutation, we have developed an important new tool
for overexpression of ABC transporters in the yeast plasma
membrane. This system allows the overexpression of functional
yeast Yor1p at a level that represents more than 10% of total
plasma membrane proteins. For comparison, overexpression of
the human MDR1 from an high copy number expression vector
in yeast by Mao and Scarborough (57) yielded protein amounts
to only 0.4% of the total yeast membrane proteins. We antici-
pate that the PDR system, which dramatically overexpresses
the functional yeast Yor1p in the plasma membrane without
associated intracellular trafficking problems, and the use of the
PDR5 promoter in strains deleted in the majority of the full-
size ABC transporter-encoding genes provides a prototype for
high level expression of orthologous ABC transporters of med-
ical interest.
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